US 7,320,875 B2 | ||
Hepatitis C virus E2 binding protein | ||
Sergio Abrignani, Castelnuovo Berardenga (Italy) | ||
Assigned to Chiron S.r.l., Siena (Italy) | ||
Filed on Mar. 09, 2006, as Appl. No. 11/372,935. | ||
Application 10/804879 is a division of application No. 09/011910, granted, now 6,737,233, previously published as PCT/IB96/00943, filed on Aug. 30, 1996. | ||
Application 11/372935 is a continuation of application No. 10/804879, filed on Mar. 18, 2004, granted, now 7,026,130. | ||
Claims priority of application No. 9517926.3 (GB), filed on Sep. 01, 1995. | ||
Prior Publication US 2006/0166193 A1, Jul. 27, 2006 | ||
Int. Cl. G01N 33/53 (2006.01); C12Q 1/00 (2006.01); C12Q 1/70 (2006.01); C07K 14/00 (2006.01); C07K 16/00 (2006.01); C07K 16/06 (2006.01); C07K 16/08 (2006.01); C07K 17/00 (2006.01) |
U.S. Cl. 435—7.92 [435/4; 435/5; 435/7.1; 435/7.9; 530/350; 530/387.1] | 4 Claims |
1. A method for screening for neutralizing hepatitis C virus (HCV) antibodies in a blood sample comprising:
providing a blood sample;
providing a known amount of (a) an HCV E2 protein and (b) a protein from a human or chimpanzee cell that has a molecular weight
of about 24 kd which binds to the E2 protein of HCV, under conditions that provide for binding between neutralizing HCV antibodies
if present in the sample and the HCV E2 protein, wherein said neutralizing HCV antibodies interfere with binding of HCV E2
to the protein of (b);
measuring the amount of the HCV E2 protein bound to the protein of (b); and
comparing the amount of the HCV E2 protein bound to the protein of (b) in the presence of the HCV antibodies to the amount
of the HCV E2 protein bound to the protein of (b) in the absence of the HCV antibodies, wherein a reduced amount of the HCV
E2 protein bound to the protein of (b) in the presence of the HCV antibodies is indicative of neutralizing HCV antibodies.
|